MXCT - Why Cell Engineering Company MaxCyte Shares Are Up Today | Benzinga
MaxCyte Inc (NASDAQ: MXCT) shares are trading higher by over 9% after the company disclosed strong preliminary Q4 and full-year 2023 revenue results.
Q4: The company projects revenue of $15.5 million - $15.7 million (vs. consensus of $10.74 million), with core revenue of $7.0 million-$7.2 million and Strategic Platform License (SPL) Program-related